Results 111 to 120 of about 577,108 (265)
Growth Factors for the Treatment of Ischemic Brain Injury (Growth Factor Treatment)
Brain Sciences, 2015 In recent years, growth factor therapy has emerged as a potential treatment for ischemic brain injury. The efficacy of therapies that either directly introduce or stimulate local production of growth factors and their receptors in damaged brain tissue ...
Amara Larpthaveesarp +2 more
doaj +1 more source
Bioscience Reports, 2013 The Eph (erythropoietin-producing hepatocellular carcinoma) B receptors are important in a variety of cellular processes through their roles in cell-to-cell contact and signalling; their up-regulation and down-regulation has been shown to have ...
Ross C. Overman +4 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
, 2010 Recombinant human non-glycosylated erythropoietin (rh-ngEpo) expressed in E. coli was attached to polyethylene glycol (PEG) chains with different sizes and structures.
Hao, Su-Juan +9 more
core +1 more source
Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs
Clinical Endocrinology, EarlyView.ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams +3 more
wiley +1 more source
Cell Proliferation, EarlyView.The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Guanheng Yang +8 more
wiley +1 more source
Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi +7 more
wiley +1 more source
Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress
, 2014 Aims: Nitrosative stress caused by ischemia contributes to poor functional recovery in hearts. A previous study showed that recombinant human erythropoietin (EPO) activates the Janus-tyrosine kinase 2/extracellular signal-regulated kinase (Jak2/ERK ...
陳益祥;黃鶴翔 +1 more
core +1 more source
Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review
Hemodialysis International, EarlyView.ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis +3 more
wiley +1 more source